HCPLive Network
Conferences
Conditions
Specialties

Amphetamines Linked to Parkinson's Risk

New research shows people who have used amphetamines such as benzedrine and dexedrine appear to be at an increased risk of developing Parkinson’s disease, according to a study released today that will be presented at the American Academy of Neurology’s 63rd Annual Meeting in Honolulu April 9 to April 16, 2011.

Benzedrine and Dexedrine are amphetamines often prescribed to increase wakefulness and focus for people with attention deficit hyperactivity disorder and narcolepsy, a disorder that can cause excessive daytime sleepiness and sudden attacks of sleep. They are also used to treat traumatic brain injuries.

The study involved 66,348 people in northern California who had participated in the Multiphasic Health Checkup Cohort Exam between 1964 and 1973 and were evaluated again in 1995. The average age of the participants at the start of the study was 36 years old. Of the participants, 1,154 people had been diagnosed with Parkinson’s disease by the end of the study.

Exposure to amphetamines was determined by two questions: one on the use of drugs for weight loss and a second question on whether people often used Benzedrine or Dexedrine. Amphetamines were among the drugs commonly used for weight loss when this information was collected.

According to the study, those people who reported using Benzedrine or Dexedrine were nearly 60 percent more likely to develop Parkinson’s than those people who didn’t take the drugs. There was no increased risk found for those people who used drugs for weight loss.

“If further studies confirm these findings, the potential risk of developing Parkinson’s disease from these types of amphetamines would need to be considered by doctors before prescribing these drugs as well as be incorporated into amphetamine abuse programs, including illicit use,” said study author Stephen K. Van Den Eeden, PhD, with the Division of Research at Kaiser Permanente Northern California in Oakland, Calif.

Van Den Eeden explained that amphetamines affect the release and uptake of dopamine, the key neurotransmitter involved in Parkinson's disease. He explained that more research needs to be completed to confirm the association and learn more about possible mechanisms.

The study was supported by Kaiser Permanente Northern California.

 
Source: American Academy of Neurology

Further Reading
Major depressive episodes (MDEs) have physical symptoms such as anhedonia, anorexia and weight loss—all of which can be triggered by activation of the immune system.In a report in JAMA Psychiatry Elaine Setiawan, PhD and colleagues said their research shows that translocator protein density intensifies during an MDE, and that shows brain inflammation.They measured translocator protein by distribution volume (TSPOVt) assessed through PET scans.
Alzheimer ’s disease (AD) has a long preclinical phase in which pathology develops years or decades before clinical symptoms. In study in JAMA Psychiatry, Robert Pietrzak, PhD, MPH and colleagues report that depression, anxiety and cognitive decline are associated with presence of Amyloidβ but that patients will benefit if their depression and anxiety are treated.
Everyone involved in the care of a child diagnosed with autism spectrum disorder (ASD) wants to know that child’s long-term prognosis. In a study in JAMA Psychiatry Peter Szatmari, MD reports on his study of 421 newly diagnosed preschoolers in a Canadian multisite longitudinal study. Data were collected over 4 years, until each child was age 6.The author found that there are several trajectories ASD can take.
More Reading